NICE rejects J&J’s Spravato for treatment-resistant depressionThe UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal Share XNICE rejects J&J’s Spravato for treatment-resistant depressionhttps://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/
J&J seeks wider use of its Spravato antidepressant in USJohnson & Johnson has filed for US approval for a new claim on the label for its nasal Share XJ&J seeks wider use of its Spravato antidepressant in UShttps://pharmaphorum.com/news/jj-seeks-wider-use-of-its-spravato-antidepressant-in-us/
FDA approves Janssen’s ketamine-based nasal antidepressantThe FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment Share XFDA approves Janssen’s ketamine-based nasal antidepressanthttps://pharmaphorum.com/news/fda-approves-janssens-ketamine-based-nasal-antidepressant/
